Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Index
-
Market Cap
49.70M
Enterprise Value
-51.27M
Income
-85.89M
Sales
22.33M
Book/sh
3.66
Cash/sh
3.72
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
119
IPO
Feb 09, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
2.23
P/B
0.36
P/C
0.35
P/FCF
-
EV/EBITDA
-
EV/Sales
-2.30
Quick Ratio
6.43
Current Ratio
6.43
Debt/Eq
0.28
LT Debt/Eq
0.24
Option/Short
No / Yes
EPS (ttm)
-2.29
EPS next Y
-1.98
EPS next Q
-0.57
EPS this Y
7.57%
EPS next Y
9.45%
EPS next 5Y
2.65%
EPS past 3/5Y
-26.57% -42.49%
Sales past 3/5Y
13.59% 219.15%
EPS Y/Y TTM
-9.30%
Sales Y/Y TTM
-50.66%
EPS Q/Q
9.28%
Sales Q/Q
-69.76%
Insider Own
21.01%
Insider Trans
-0.14%
Inst Own
17.44%
Inst Trans
-2.01%
ROA
-34.71%
ROE
-49.02%
ROIC
-50.27%
Gross Margin
76.56%
Oper. Margin
-415.48%
Profit Margin
-384.61%
SMA20
8.24%
SMA50
1.12%
SMA200
-22.65%
Trades
Shs Outstand
37.65M
Shs Float
29.74M
52W High
3.95 -66.58%
52W Low
1.13 16.81%
Volatility
5.71% 5.49%
ATR (14)
0.07
RSI (14)
57.81
Beta
0.67
Rel Volume
1.69
Avg Volume
170.03K
Volume
287,466
Perf Week
10.00%
Perf Month
-0.75%
Perf Quarter
-2.94%
Perf Half Y
-20.96%
Perf YTD
-18.52%
Perf Year
-21.89%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
1.25
Price
1.32
Change
5.60%
Date Action Analyst Rating Change Price Target Change
TodayResumed Chardan Capital Markets Buy $5
May-07-24Initiated H.C. Wainwright Buy $10
May-02-24Downgrade JP Morgan Overweight → Neutral $16 → $6
Mar-05-24Initiated Wells Fargo Overweight $25
Mar-05-24Initiated TD Cowen Outperform
Mar-05-24Initiated JP Morgan Overweight $16
Mar-05-24Initiated Jefferies Buy $23
Mar-05-24Initiated Chardan Capital Markets Buy $21
Mar-05-24Initiated BMO Capital Markets Outperform $22
Jun-05-26 03:45PM
May-28-26 08:00AM
May-11-26 04:18PM
04:05PM
Apr-16-26 07:00AM
12:15PM Loading…
Apr-13-26 12:15PM
Mar-05-26 05:30PM
04:28PM
04:05PM
Feb-26-26 05:30PM
Feb-23-26 04:05PM
Jan-12-26 08:30AM
Dec-02-25 12:32PM
Dec-01-25 07:00AM
Nov-17-25 08:00AM
05:20AM Loading…
Nov-12-25 05:20AM
Nov-11-25 05:10PM
04:09PM
04:02PM
04:01PM
Nov-10-25 05:45PM
Nov-06-25 08:50AM
Nov-05-25 05:35PM
Oct-22-25 10:02AM
Oct-20-25 12:00PM
Aug-12-25 05:40PM
05:25PM
04:37PM
04:05PM
Aug-11-25 04:05PM
08:35AM Loading…
Aug-07-25 08:35AM
Jul-29-25 10:23AM
Jul-18-25 10:06AM
09:41AM
Jul-14-25 11:12AM
May-14-25 06:00AM
May-13-25 05:40PM
04:42PM
04:30PM
May-08-25 09:30AM
May-06-25 07:15AM
May-02-25 07:00AM
Apr-01-25 11:50AM
Mar-17-25 04:05PM
Mar-13-25 06:19AM
Feb-11-25 08:55AM
Jan-28-25 08:00AM
Jan-22-25 11:54AM
Jan-16-25 08:55AM
Jan-15-25 08:55AM
Jan-08-25 04:05PM
Dec-11-24 06:30PM
Dec-09-24 09:16PM
Dec-08-24 06:05AM
Nov-18-24 12:00PM
Nov-13-24 04:37PM
04:05PM
Nov-05-24 04:05PM
Oct-29-24 05:45AM
Oct-24-24 08:04AM
Oct-23-24 05:45AM
Oct-14-24 08:58PM
Oct-01-24 03:14PM
Sep-19-24 07:15PM
Sep-03-24 04:05PM
Aug-29-24 07:32PM
Aug-28-24 06:10PM
Aug-26-24 09:00PM
Aug-14-24 08:11AM
08:05AM
Aug-12-24 06:29PM
Aug-05-24 09:00PM
Jun-03-24 04:30PM
04:17PM
May-29-24 04:00PM
May-14-24 10:54PM
04:05PM
May-04-24 10:49AM
May-02-24 06:04AM
May-01-24 04:00PM
01:53PM
Apr-08-24 08:00AM
Mar-27-24 09:16AM
Feb-29-24 04:30PM
Feb-13-24 04:35PM
Feb-08-24 10:16PM
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Ph.D.Dr. Jian Irish M.B.A.
Chief Financial OfficerMs. Pamela M. Wapnick M.B.A.
Gen-er-al Coun-selMr. Matthew L. Wein J.D.
Co-Founder & Member of Scientific Advisory BoardDr. Joseph Knowles M.D.
Senior Vice Pres-i-dent of Tech-ni-cal Devel-op-ment & Oper-a-tionsMr. Mark Leonard
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wapnick PamelaChief Financial OfficerJun 05 '26Sale1.302,8843,746208,491Jun 10 11:23 AM
Irish JianSee RemarksJun 05 '26Sale1.303,7374,854377,533Jun 10 11:21 AM
Wein MatthewSee RemarksJun 05 '26Sale1.30558725126,491Jun 10 11:19 AM
Wapnick PamelaChief Financial OfficerMar 05 '26Sale1.601,5812,530187,375Mar 09 05:16 PM
Wein MatthewSee RemarksMar 05 '26Sale1.60482771114,549Mar 09 05:16 PM
Irish JianChief Executive OfficerMar 05 '26Sale1.601,6072,571333,770Mar 09 05:15 PM
Thomas Brian C.DirectorDec 05 '25Sale1.773,8306,7862,510,960Dec 08 01:56 PM
Wein MatthewSee RemarksDec 05 '25Sale1.77199353115,031Dec 08 01:51 PM
Wapnick PamelaChief Financial OfficerDec 05 '25Sale1.771,5762,793188,956Dec 08 01:49 PM
Irish JianChief Executive OfficerDec 05 '25Sale1.771,6022,839563,839Dec 08 01:38 PM
Thomas Brian C.DirectorSep 05 '25Sale1.812,7014,8892,514,790Dec 01 07:34 PM
Wapnick PamelaChief Financial OfficerSep 05 '25Sale1.811,5762,85370,532Dec 01 07:32 PM
Irish JianChief Executive OfficerSep 05 '25Sale1.811,6022,900316,941Dec 01 07:28 PM
Wein MatthewSee RemarksSep 05 '25Sale1.8119936019,230Dec 01 06:37 PM
Noonberg Sarah B.FORMER OFFICERSep 11 '25Proposed Sale1.9035,83268,081Sep 11 04:25 PM
Sebastian BernalesAffiliateJul 09 '25Proposed Sale1.91769,8451,470,404Jul 09 06:34 PM